We are live on ! Find out more
TLP

Tri Locum Partners Portfolio holdings

AUM $713M
1-Year Est. Return 68.92%
This Fund
S&P 500
This Quarter Est. Return
+19.03%
1 Year Est. Return
+68.92%
3 Year Est. Return
+377.81%
5 Year Est. Return
+1,289.15%
10 Year Est. Return
–
AUM
$417M
AUM Growth
+$21.9M
Cap. Flow
-$16.8M
Cap. Flow %
-4.02%
Top 10 Hldgs %
79.89%
Holding
27
New
2
Increased
11
Reduced
6
Closed
7

Top Buys

Rank Stock Value
1
PFE icon
Pfizer
PFE
+$33.1M
2
STVN icon
Stevanato
STVN
+$26.2M
3
VRNA
Verona Pharma
VRNA
+$14.6M
4
PCVX icon
Vaxcyte
PCVX
+$14.3M
5
NTRA icon
Natera
NTRA
+$9.97M

Top Sells

Rank Stock Value
1
ASND icon
Ascendis Pharma A/S
ASND
+$31.1M
2
AMGN icon
Amgen
AMGN
+$25.7M
3
AXSM icon
Axsome Therapeutics
AXSM
+$18.7M
4
REGN icon
Regeneron Pharmaceuticals
REGN
+$18.4M
5
INSM icon
Insmed
INSM
+$12.7M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PFE icon
1
Pfizer
PFE
$143B
$50.2M 12.01%
1,732,935
+1,136,016
+190% +$33.1M
TEVA icon
2
Teva Pharmaceuticals
TEVA
$37.3B
$49.7M 11.9%
2,755,737
+205,430
+8% +$3.6M
NTRA icon
3
Natera
NTRA
$38.9B
$40.3M 9.65%
317,439
+86,854
+38% +$9.97M
STVN icon
4
Stevanato
STVN
$5.23B
$37.4M 8.95%
1,867,938
+1,302,516
+230% +$26.2M
ARGX icon
5
argenx
ARGX
$53.8B
$33.9M 8.11%
62,474
-12,084
-16% -$6.11M
INSP icon
6
Inspire Medical Systems
INSP
$1.46B
$32M 7.66%
151,429
+18,153
+14% +$3.15M
PCVX icon
7
Vaxcyte
PCVX
$8.12B
$31.1M 7.44%
271,922
+158,578
+140% +$14.3M
AVDL
8
DELISTED
Avadel Pharmaceuticals
AVDL
$21.8M 5.22%
1,660,955
+471,437
+40% +$7.18M
UTHR icon
9
United Therapeutics
UTHR
$22.7B
$19.7M 4.72%
54,926
+4,826
+10% +$1.63M
LEGN icon
10
Legend Biotech
LEGN
$4.31B
$17.7M 4.23%
362,270
+5,738
+2% +$306K
VRNA
11
DELISTED
Verona Pharma
VRNA
$17.1M 4.09%
+593,980
New +$14.6M
INSM icon
12
Insmed
INSM
$23.5B
$10.5M 2.52%
143,920
-172,581
-55% -$12.7M
BHVN icon
13
Biohaven
BHVN
$2.32B
$9.65M 2.31%
+193,195
New +$7.52M
MRUS
14
DELISTED
Merus
MRUS
$9.6M 2.3%
192,157
-143,357
-43% -$7.48M
DFTX
15
Definium Therapeutics
DFTX
$5.88B
$9.46M 2.27%
1,662,953
+1,280,898
+335% +$8.91M
MDGL icon
16
Madrigal Pharmaceuticals
MDGL
$12.8B
$9.19M 2.2%
43,287
-22,065
-34% -$5.64M
AXSM icon
17
Axsome Therapeutics
AXSM
$11.8B
$8.24M 1.97%
91,721
-214,792
-70% -$18.7M
NVO
18
Novo Nordisk
NVO
$223B
$8.01M 1.92%
67,257
+3,446
+5% +$460K
KRRO icon
19
Korro Bio
KRRO
$177M
$2.14M 0.51%
64,014
-7,414
-10% -$312K
FEMY icon
20
Femasys
FEMY
$9.09M
$34K 0.01%
1,530
– –
ALNY icon
21
Alnylam Pharmaceuticals
ALNY
$35.7B
– –
-45,000
Closed -$10.9M
AMGN icon
22
Amgen
AMGN
$198B
– –
-82,271
Closed -$25.7M
ASND icon
23
Ascendis Pharma A/S
ASND
$17.1B
– –
-227,762
Closed -$31.1M
OCUL icon
24
Ocular Therapeutix
OCUL
$1.96B
– –
-514,642
Closed -$3.52M
PRAX icon
25
Praxis Precision Medicines
PRAX
$8.77B
– –
-75,319
Closed -$3.12M
1
2

Similar funds

DCM
Defilade Capital Management Emeryville, California $712M AUM
AMPWP
Alvarez & Marsal Private Wealth Partners West Palm Beach, Florida $712M AUM
DCM
Dimension Capital Management Coral Gables, Florida $713M AUM 18.57% 1-Year Est. Return
IWP
Insight Wealth Partners Plano, Texas $713M AUM 16.55% 1-Year Est. Return
LS
Leelyn Smith Geneva, Illinois $713M AUM 17.46% 1-Year Est. Return
PCS
Personal CFO Solutions Chester, New Jersey $712M AUM 25.3% 1-Year Est. Return
ACGDR
Atmos Capital Gestao de Recursos Leblon - Rio De Janeiro, Brazil $714M AUM 35.97% 1-Year Est. Return
GEA
Glen Eagle Advisors Kingston, New Jersey $714M AUM 18.87% 1-Year Est. Return

Tri Locum Partners's Q3 2024 Portfolio in Review

As of Q3 2024, Tri Locum Partners held 27 positions worth $417M, up 5.5% from $395M the previous quarter. Its ten largest holdings account for 80% of the portfolio.

Tri Locum Partners withdrew a net $16.8M in Q3 2024, closing 7 positions and reducing 6 holdings. Its most notable exit was Ascendis Pharma A/S, an estimated $31.1M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

Against the trend, Tri Locum Partners opened a new position in Verona Pharma worth $17.1M.

  • Tri Locum Partners's largest Q3 2024 buy was Verona Pharma: 593,980 shares worth $17.1M.
  • Tri Locum Partners added most to Pfizer in Q3 2024, an estimated $33.1M increase.
  • Tri Locum Partners's biggest Q3 2024 reduction was Axsome Therapeutics, cutting an estimated $18.7M.
  • Tri Locum Partners fully exited Ascendis Pharma A/S in Q3 2024, selling an estimated $31.1M.
  • Tri Locum Partners's ten largest holdings make up 80% of its $417M portfolio in Q3 2024.
  • Tri Locum Partners opened 2 new positions and closed 7 in Q3 2024.
  • Tri Locum Partners's portfolio value rose 5.5% quarter-over-quarter to $417M.

Based on Tri Locum Partners's 13F filing for Q3 2024, filed 14 Nov 2024.